| 1 |
Cellular conditions of weakly chelated magnesium ions strongly promote RNA stability and catalysis
Ryota Yamagami, Jamie L. Bingaman, Erica A. Frankel et al. · Nature Communications
Open access |
25 May 2018 |
86 |
| 2 |
White adipose tissue cells and the progression of cachexia: inflammatory pathways
Rodrigo Xavier das Neves, José Cesar Rosa Neto, Alex Shimura Yamashita et al. · Journal of Cachexia Sarcopenia and Muscle
Open access |
7 Jul 2015 |
56 |
| 3 |
Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains
Rama Devudu Puligedda, Diana V. Kouiavskaia, Sharad P. Adekar et al. · Antiviral Research
|
10 May 2014 |
22 |
| 4 |
Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development
Wayne Chester Koff, Rino Rappuoli, Stanley Alan Plotkin · Journal of Molecular Biology
|
18 Apr 2023 |
18 |
| 5 |
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation
John P. Dowling, Pavel A. Nikitin, Fang Shen et al. · mAbs
Open access |
22 May 2023 |
16 |
| 6 |
A consumer charter for genomic services
Fred David Ledley · Nature Biotechnology
|
Aug 2002 |
15 |
| 7 |
Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor
Rashmi Sharma, Huiwu Zhao, Fetweh H. Al‐Saleem et al. · Molecular Immunology
Open access |
Nov 2013 |
15 |
| 8 |
Enhanced Neutralization Potency of Botulinum Neurotoxin Antibodies Using a Red Blood Cell-Targeting Fusion Protein
Sharad P. Adekar, Andrew T. Segan, Cindy Si Chen et al. · PLoS ONE
Open access |
2 Mar 2011 |
14 |
| 9 |
IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2
Pavel A. Nikitin et al. · Science Immunology
Open access |
30 Jun 2022 |
12 |
| 10 |
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein
Jillian M. DiMuzio, Baron C. Heimbach, Raymond J. Howanski et al. · Vaccine X
Open access |
24 Apr 2021 |
10 |
| 11 |
1766P Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors
B. Kasper, Mrinal M. Gounder, Rashmi K Chugh et al. · Annals of Oncology
Open access |
Sep 2024 |
4 |
| 12 |
Enzymatic Pathway for Kupyaphore Degradation in Mycobacterium tuberculosis: Mechanism of Metal Homeostasis and Turnover
Rashmi S. Bhosale, Arnab Kumar Chakraborty, Tsung-Yun Wong et al. · ACS Chemical Biology
|
30 Jun 2025 |
2 |
| 13 |
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
Daping Zhang, Adekemi B. Taylor, Jie Janet Zhao et al. · Clinical Pharmacokinetics
Open access |
Oct 2024 |
2 |
| 14 |
Repression of LKB1 by miR-17∼92 sensitizes MYC -dependent lymphoma to biguanide treatment
Said Izreig, Alexandra Gariepy, Ariel O. Donayo et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
20 Dec 2019 |
2 |
| 15 |
Hypomorphic RAG2 Deficiency Promotes Selection of Self-Reactive B Cells
Christopher D. Thouvenel et al. · Journal of Clinical Immunology
Open access |
15 Jan 2025 |
1 |
| 16 |
Autonomic Function Recovery in Post-Covid-19 Young Adults After Immunization: An Observational Follow up Case-control Study
Ana Paula Coelho Figueira Freire, Shaan N. Amin, Fábio Santos Lira et al. · Preprints.org
PreprintOpen access |
28 Nov 2022 |
1 |
| 17 |
Diversification and shared features of tumor‐binding antibody repertoires in tumor, sentinel lymph node and blood of three patients with breast cancer
Stephanie C. Pero, Aaron M. Rosenfeld, Girja S. Shukla et al. · Clinical & Translational Immunology
Open access |
2022 |
1 |
| 18 |
Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
Pavel A. Nikitin et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
19 Oct 2021 |
1 |
| 19 |
Scientific and Regulatory Policy Committee Points to Consider* for Determining and Reporting Cause of Death/Moribundity in Non-Rodent Species in Toxicity Studies
Karyn A. Colman, Kathleen A. Funk, Michael Boyle et al. · Toxicologic Pathology
|
20 Mar 2025 |
0 |